Elixinol Wellness AI Stock Analysis
Want to see AU:EXL full AI Analyst Report?
Elixinol Wellness (EXL) AI Stock Analysis
Elixinol Wellness
(ASX:EXL)
The overall score is at the minimum of 37, reflecting severe financial distress. The primary drivers are collapsing profitability (gross margin fell to 4.9%), persistent net losses, and six years of negative operating cash flow. Rising leverage and declining equity further weaken the balance sheet. The lack of technical data and a negative P/E ratio offer no counterbalance, resulting in a uniformly weak profile.
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 830.47K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- -1.13
- Revenue Growth
- -4.87%
- EPS Growth
- -9.78%
- Country
- Australia
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp...
How the Company Makes Money
Elixinol Wellness makes money primarily by selling branded hemp/CBD wellness products to consumers and trade customers. Its core revenue streams are (1) direct-to-consumer sales via company-controlled e-commerce channels, where the company captures t...
Elixinol Wellness Earnings Call Summary
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).
Elixinol Wellness Financial Statement Overview
Summary
Financial health is critically weak. Revenue growth slowed to 4% in 2025, gross margin collapsed to 4.9%, and net losses widened to -$5.5M. The balance sheet shows declining equity and rising debt-to-equity (0.53), while operating cash flow remains negative for six consecutive years. Profitability and cash generation are major concerns.
Income Statement
20Very NegativeBalance Sheet
35NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.05M | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 1.66M | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -1.95M | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -3.48M | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | ||||||
| Total Assets | 15.17M | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 996.00K | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 4.03M | 3.73M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.81M | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 6.36M | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | ||||||
| Free Cash Flow | -2.62M | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -2.54M | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -173.00K | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 2.52M | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Peers Comparison
Overall Rating
AU:VLS77Outperform
AU:CAN53Neutral
AU:LGP51.5Neutral
AU:PKP39Underperform
AU:VIT39Underperform
AU:EXL37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | AUD 146.51M | 13.30 | 19.91% | 5.45% | 12.19% | 22.36% | |
| 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
| 52Neutral | AUD 55.47M | -14.56 | -1.67% | ― | 15.21% | -141.82% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 39Underperform | AUD 18.75M | -5.07 | 4388.00% | ― | -19.73% | 50.34% | |
| 39Underperform | AUD 12.59M | -2.54 | -9.80% | ― | 5.74% | -222.22% | |
| 37Underperform | AUD 2.72M | -0.59 | -50.35% | ― | -4.87% | -9.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EXL | Elixinol Wellness Ltd | 0.01 | 0.00 | 50.00% | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:VLS | Vita Life Sciences Limited | 2.66 | 0.37 | 16.26% | |
| AU:LGP | Little Green Pharma Ltd. | 0.07 | -0.06 | -48.46% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.00 | -26.32% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -69.84% |
Elixinol Wellness Corporate Events
Elixinol Wellness Plans Major ASX Share Placement
Elixinol Wellness Limited has notified the ASX of a proposed equity issue via placement or similar mechanism, involving up to 666,666,666 ordinary fully paid shares. The proposed issue date is set for 7 December 2026, with the company agreeing to com...
Elixinol Wellness Moves to Acquire Data-Rich Platform Vitable
Elixinol Wellness Limited, listed on the ASX under ticker EXL, operates in the consumer wellness and health products sector. The company focuses on everyday wellness solutions and distributes its products through retail, wholesale and direct-to-consu...
Elixinol to Buy Vitable in Bid to Build Scaled Wellness Platform
Elixinol Wellness has agreed to acquire Australian personalised supplement subscription business Vitable, adding more than $5 million in revenue and taking its annual turnover above $20 million. The deal, paid in EXL shares with a largely performance...
Elixinol Wellness Tightens Governance After Late ASX Director Interest Filing
Elixinol Wellness has disclosed that a Change of Director’s Interest Notice for CEO and Executive Director Natalie Butler was lodged with the ASX later than required under listing rules. The delay related to the sale of a small parcel of Butler’s sha...
Elixinol Wellness Converts Convertible Notes into Equity Under Cleansing Notice
Elixinol Wellness has issued 15,913,534 fully paid ordinary shares following the conversion of 100,000 convertible notes at a set price under its previously approved Convertible Note Facility. The issuance was carried out without a prospectus under t...
Elixinol Wellness Seeks ASX Quotation for 15.9 Million New Shares
Elixinol Wellness Limited has applied to the ASX for quotation of 15,913,534 new ordinary fully paid shares, to be issued and listed under its existing EXL ticker on September 17, 2026. This move increases the total number of quoted securities on iss...
Elixinol Wellness Completes U.S. Exit to Focus on Australian Wellness Platform
Elixinol Wellness has provided a business update alongside confirmation of the completion of its U.S. divestment, signalling a strategic shift toward its Australian nutrition and wellness operations. The update, based on audited interim financial sta...
Elixinol Wellness Completes Sale of U.S. Business to Refocus on Australia
Elixinol Wellness Limited has completed the divestment of its United States business to Ananda Health Inc., finalising a sale that delivers headline consideration of about A$465,000 through a mix of upfront, deferred and contingent payments. The tran...
Elixinol Wellness Boosts Equity Base with Convertible Note Conversion
Elixinol Wellness has issued 24,210,906 fully paid ordinary shares following the conversion of 135,000 convertible notes at a price of $0.005576 per share, in line with a previously approved convertible note facility. The company confirmed the shares...
Elixinol seeks ASX quotation for 24.2 million new shares
Elixinol Wellness Limited has applied to the ASX for quotation of 24,210,906 new ordinary fully paid shares, with an issue date of 3 September 2026. The move increases the number of Elixinol securities on issue and may influence the company’s capital...
Elixinol Wellness Narrows Loss and Reshapes Portfolio With US Exit
Elixinol Wellness reported a significantly improved operating performance in the first half of FY26, with revenue from continuing operations rising 5.8% to $7.2 million and gross margin expanding to 43% from 33%. Operating expenses fell 25% to $3.3 m...
Elixinol Wellness Narrows Half-Year Loss Amid Ongoing Balance Sheet Strain
Elixinol Wellness reported a modest 2.2% increase in revenue to $7.8 million for the half-year to 30 June 2026, while cutting its after-tax loss by 65.4% to $1.1 million. The group’s basic and diluted loss per share narrowed to 0.26 cents, reflecting...
Elixinol Wellness Issues Over 1 Million New Convertible Notes
Elixinol Wellness Limited has notified the market of the issue of new unquoted convertible notes. The company will issue 1,055,800 convertible notes, documented as a new class of securities, with an issue date of 26 August 2026.The move adds to Elixi...
Elixinol Wellness to Exit U.S. Hemp Business in A$465,000 Deal
Elixinol Wellness has agreed to divest its U.S. business to Ananda Health, Inc. in a binding asset sale valued at up to A$465,000, structured with upfront payments, deferred consideration, a regulatory contingent amount and a revenue-based earn-out o...
Elixinol Wellness Builds Margin-Strong Platform for Growth
Elixinol Wellness, trading on the ASX as EXL, is a functional nutrition and everyday wellness company focused on healthy ageing and metabolic health. It distributes products through Priceline, major grocery outlets, ecommerce and B2B partners, and is...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
